Published
5 months agoon
By
adminWe are exiting our position in Abbott Laboratories , selling 250 shares at roughly $129. Following the trade, Jim Cramer’s Charitable Trust will no longer hold a position in Abbott. Abbott Labs reported a mixed quarter on Wednesday as strength in its medical devices business was partially offset by softness in its nutrition and diagnostics units. For such a high-quality company with a long track record of beating analyst estimates and raising its full-year outlook, this was the second consecutive quarter where it either cut or maintained its guidance. Shares of this diversified health-care company have had a solid year, gaining about 14% and outperforming the broader health-care sector’s gain of about 4%. However, the stock has stalled out since July alongside the lack of positive earnings revisions from the second-quarter report. Another quarter without a guide up could mean the stock will continue to trade sideways. Instead of holding on to this tiny position, we are freeing up this capital for better opportunities. Finally, this sale will increase our cash position to around 7.5% of the portfolio. Due to the market’s sensitivity to trade relations with China, having this extra cash will give us more flexibility should we see another headline-driven sell-off. From this sale, we will realize an average gain of about 24% on stock purchased in April and May 2024. (See here for a full list of the stocks in Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
This industrial giant is emerging as a big AI play, says Wells Fargo
Novo Nordisk’s strategy tested as investors push back on board revamp
Alibaba plans AI subscriptions, stablecoin-like payments with JPMorgan
UK borrowing costs spike on report government to scrap plans to raise income tax
Trump’s threatened the BBC with a $1B lawsuit: Here’s what’s going on
UBS’s picks for global returns next year
Wells Fargo sees Caterpillar continuing to roar higher, emerging as an artificial intelligence play. The bank initiated shares of...
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic...
Key Points Alibaba plans to use “tokenization” of payments for cross-border transactions in its business-to-business arm. Kuo Zhang, president...
Rachel Reeves, U.K. chancellor of the exchequer, delivers a speech in London, UK, on Tuesday, Nov. 4, 2025. Bloomberg...
US President Donald Trump speaks to reporters as he arrives at Palm Beach International Airport on Oct. 31,...
Investors looking for global diversification opportunities should look to a specific subset of stocks in Europe, according to UBS...
Eakarat Buanoi | Istock | Getty Images LISBON, Portugal — Top tech executives told CNBC they’re concerned about...
Tan Su Shan, deputy chief executive officer and managing director of institutional banking at DBS Group Holdings Ltd., speaks during...
CHENGDU, CHINA – OCTOBER 18: People walk past the Louis Vuitton store at Taikoo Li, a high-end shopping area that...
The United States said Thursday it will remove tariffs on some foods and other imports from Argentina, Ecuador, Guatemala and...
